FLUID-BAG MULTI — superior logistics for liquid and semi-solid pharmaceutical products - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

FLUID-BAG MULTI – superior logistics for liquid and semi-solid pharmaceutical products

provides comprehensive 900 and 1000 litre flexible IBC systems for liquid and semi-solid products, including filling and discharging equipment. The GMP compliant container system is designed to guarantee uniform liquid, maximise payload and minimise discharge residue (0.5% residue).

The MULTI container combines the flexibility and space-saving advantages of both single-trip and multi-trip containers. The container consists of:

  • a replaceable, single-trip inner container
  • a reusable multi-trip transport bag
  • a reusable steel transport pallet with 4 steel poles.

Alternative liner combinations are available, gamma irradiation is also possible. The container can be used for external transports, intermediate storage, for transport between production, store room and packing department etc.

The FLUID-BAG system is used for storage and transportation of a wide range of liquids where protection from bacteria, particle, oxidation, taste or moisture contamination is needed. The containers are widely used for ointments, lotions, suspensions and other liquid or semi-solid products.

Contact details

Fluid-Bag Ltd
Bottenviksvägen 54-56
68600 Jakobstad
Finland
Tel. +358 20 779 0444
E-mail: office@fluid-bag.com
www.fluid-bag.com

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FindPharma Custom Search

Click here